key: cord-0729992-pvgaroo3 authors: Sapir, E.; Moisa, N.; Litvin, A.; Malki, E.; Vorobiof, D. A. title: 1594P SARS-CoV-2 vaccines in cancer patients (pts), real-world data (RWD) from 1069 Belong.life users date: 2021-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2021.08.1587 sha: 932be83b3c29026467880e76f37bb74bff8a36a1 doc_id: 729992 cord_uid: pvgaroo3 Background: The COVID-19 pandemic continues to have a serious impact on many people, including cancer pts. The US CDC and oncology groups (ASCO, ESMO, ACS) made recommendations as to what high risk groups should be vaccinated first which includes cancer pts. Users of Belong.life, a worldwide, free, and voluntary, digital health application for cancer pts, replied to a targeted survey including demographic & clinical questions related to the pts cancers, ongoing therapies and the Covid 19 vaccination characteristics, and interactions. Methods: In this prospective study, 1069 cancer pts, Belong.life users, voluntarily replied to a survey asking demographic and clinical questions related to their Covid 19 vaccination and cancer status characteristics. Results: Most of the pts were North American based (91 %), with 6.3 % from Europe and 2.6% from the rest of the world. 72% were between 50-69 years of age, and 79.5% were females. Five most common diagnosis were Breast Cancer (35.2%), gynecological (14.4%), gastrointestinal (13.3%), lung cancers (9.7%) and genitourinary (7%). 59% of the pts received chemotherapy,14.2% immunotherapy and 32.8% had radiotherapy over the past 12 months prior to receive the Covid 19 vaccination, which consisted of mRNA vaccines in 82.2% (Pfizer 46.2%, Moderna 36%). 4.9% of the pts refused vaccination. 82.3% of the pts had none (39.3%) or mild (43%) side-effects (S/E) and only 2.4% reported severe S/E. Most S/E lasted 1-3 days (89.4%) consisting mainly of sore arm (42.5%), headache (23.3%), fatigue (21.1%), and temperature (18.5%). Swollen lymph-nodes and allergic reactions were only reported in 0.7% (each). 49% of the pts were vaccinated while actively engaged on treatment, and in 96% there was no delay, interruption, or stoppage of the anticancer therapy. Conclusions: This is the first large report on Real word data voluntarily obtained from 1069 Belong.life users undergoing anticancer treatment with 90% of them receiving a Covid 19 vaccination. The large majority of pts had none or mild S/E (82.3%), and those were short lived (1-3 days in 89.4%) while only in 2% it was graded as severe. In 96% of the pts their ongoing anticancer therapy did not necessitate to be delayed, interrupted, or stopped. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: E. Sapir: Financial Interests, Personal, Advisory Role, Consultant: Belong.life;Financial Interests, Personal, Advisory Role, Consultant: MSD;Financial Interests, Personal, Advisory Role, Consultant: AstraZeneca. N. Moisa: Financial Interests, Personal, Full or part-time Employment: BelongTail. A. Litvin: Financial Interests, Personal, Full or part-time Employment: BelongTail. E. Malki: Financial Interests, Personal, Full or part-time Employment: BelongTail;Financial Interests, Personal, Full or part-time Employment: Belong.life. D.A. Vorobiof: Financial Interests, Personal, Full or part-time Employment: BelongTail;Financial Interests, Personal, Full or part-time Employment: Belong.life. the vaccination. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast or gynecological cancer. The aim was to improve counseling of our patients in clinical routine. Methods: Since March 15 th 2021, patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate (0-2 days) and late side effects (within two weeks after vaccination). Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to the vaccination were documented. Furthermore, the willingness of non-vaccinated patients to be vaccinated was assessed. The collected data were anonymously analyzed as a part of routine quality assurance. Results: By May 10 th 2021, 111 out of 217 (51.1%) interviewed patients had received at least one shot of COVID-19 vaccine and 21 patients both shots. More than half of the vaccinated patients were >55y (60.2%; mean: 60.7y, range 30-92y); 69% with UICC/ FIGO stage III/IV cancer. 74.6% received Conmirnaty (BioNTech/ Pfizer), 18.9% Vaxzevria (AstraZeneca) and 6.5% Covid-19 Vaccine Moderna. After the first shot, 33.3% of the patients described no side effects, 49.1% reported a local reaction (swelling or pain), 23.4% flu-like symptoms, 10.8% headache and 3.6% nausea. 11 patients had symptoms that lasted longer than two days. In 11 cases, COVID-19 vaccination had an impact on delivery of the systemic therapy (n¼10 postponements of therapy and n¼1 dose reduction). 61.3% of the non-vaccinated patients (in total n¼118) were already registered to get vaccinated; 32.8% chose to postpone vaccination for personal reasons; 5% refused vaccination. Conclusions: Breast and gynecological cancer patients appear to tolerate COVID-19 vaccination well under systemic therapy and only in few cases the vaccination interfered with the treatment schedule. Updated results will be presented at the ESMO Congress. Legal entity responsible for the study: LMU University Hospital. Funding: Has not received any funding. 7%) and genitourinary (7%). 59% of the pts received chemotherapy,14.2% immunotherapy and 32.8% had radiotherapy over the past 12 months prior to receive the Covid 19 vaccination, which consisted of mRNA vaccines in 82.2% (Pfizer 46.2%, Moderna 36%). 4.9% of the pts refused vaccination. 82.3% of the pts had none (39.3%) or mild (43%) side-effects (S/E) and only 2.4% reported severe S/E. Most S/E lasted 1-3 days (89.4%) consisting mainly of sore arm (42.5%), headache (23.3%), fatigue (21.1%), and temperature (18.5%). Swollen lymph-nodes and allergic reactions were only reported in 0.7% (each). 49% of the pts were vaccinated while actively engaged on treatment, and in 96% there was no delay, interruption, or stoppage of the anticancer therapy. Conclusions: This is the first large report on Real word data voluntarily obtained from 1069 Belong.life users undergoing anticancer treatment with 90% of them receiving a Covid 19 vaccination. The large majority of pts had none or mild S/E (82.3%), and those were short lived (1-3 days in 89.4%) while only in 2% it was graded as severe Consultant: MSD; Financial Interests, Personal, Advisory Role, Consultant: AstraZeneca. N. Moisa: Financial Interests, Personal, Full or part-time Employment: BelongTail. A. Litvin: Financial Interests, Personal, Full or part-time Employment: BelongTail. E. Malki: Financial Interests, Personal, Full or part-time Employment: BelongTail; Financial Interests, Personal, Full or part-time Employment: Belong.life. D.A. Vorobiof: Financial Interests, Personal, Full or part-time Employment: BelongTail; Financial Interests, Personal, Full or part-time Employment: Belong 1595P Acceptance of COVID-19 vaccination among cancer patients in an Irish cancer centre Hospitalised cancer patients have a three times higher risk of death (14%) from COVID-19 than the general public. Vaccination provides an unprecedented opportunity to decrease morbidity & mortality, however, there is a limited data regarding cancer patients' attitudes towards COVID-19 vaccination. Methods: An anonymised questionnaire was completed by volunteering cancer patients attending the ambulatory care unit of a large tertiary cancer centre Most (78%) had a good performance status (PS ¼ 0-1) & lung was the most frequent (28%) cancer type. Eight (6%) had previous COVID-19 infection. Among respondents, 128 (90%) intended on getting vaccinated, 12 (8%) were unsure & three (2%) would refuse. Those intent on vaccination were less concerned with side effects Almost 20% (n¼28) reported that they were more likely to receive the flu vaccine due to the pandemic. Twelve (8%) identified attending their GP as a barrier, with 97% (n¼135) willing to attend hospital for vaccination. While this service is free, 69% (n¼99) were willing to pay